文献速递癫痫

1990-2016年全球癫痫负担的系统分析

Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
PubMed 文献 · Lancet Neurol · 2019-02-14

该研究基于全球疾病负担研究数据,评估195个国家和地区1990-2016年癫痫的死亡、患病率和伤残调整生命年。

要点

  • 1990-2016年癫痫年龄标化死亡率和DALY率显著下降。

核心结论

  • 尽管1990-2016年癫痫疾病负担下降,癫痫仍是残疾和死亡的重要原因。

研究设计与样本

  • 基于全球疾病负担研究2016数据,评估195个国家和地区1990-2016年癫痫负担,按年龄、性别、年份、地点和社会人口指数分析。

关键数值与推荐

  • 低与高SDI五分位国家间年龄标化DALY率差异,三分之一归因于低资源地区癫痫严重程度更高,三分之二归因于低SDI国家YLL率更高。

临床怎么用

  • 全球癫痫负担数据可用于卫生保健规划和资源分配。
  • 改善低收入国家现有治疗的可及性可能大幅减轻癫痫负担。
  • 需在人群代表性调查中标准化收集癫痫数据,尤其是严重程度、病因和治疗信息。

局限性

  • 部分国家数据缺乏或稀疏,影响估计准确性。
  • 需额外收集癫痫严重程度、病因和治疗数据以强化估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seizures and their consequences contribute to the burden of epilepsy because they can cause health loss (premature mortality and residual disability). Data on the burden of epilepsy are needed for health-care planning and resource allocation. The aim of this study was to quantify health loss due to epilepsy by age, sex, year, and location using data from the Global Burden of Diseases, Injuries, and Risk Factors Study. METHODS: We assessed the burden of epilepsy in 195 countries and territories from 1990 to 2016. Burden was measured as deaths, prevalence, and disability-adjusted life-years (DALYs; a summary measure of health loss defined by the sum of years of life lost [YLLs] for premature mortality and years lived with disability), by age, sex, year, location, and Socio-demographic Index (SDI; a compound measure of income per capita, education, and fertility). Vital registrations and verbal autopsies provided information about deaths, and data on the prevalence and severity of epilepsy largely came from population representative surveys. All estimates were calculated with 95% uncertainty intervals (UIs). FINDINGS: In 2016, there were 45·9 million (95% UI 39·9-54·6) patients with all-active epilepsy (both idiopathic and secondary epilepsy globally; age-standardised prevalence 621·5 per 100 000 population; 540·1-737·0). Of these patients, 24·0 million (20·4-27·7) had active idiopathic epilepsy (prevalence 326·7 per 100 000 population; 278·4-378·1). Prevalence of active epilepsy increased with age, with peaks at 5-9 years (374·8 [280·1-490·0]) and at older than 80 years of age (545·1 [444·2-652·0]). Age-standardised prevalence of active idiopathic epilepsy was 329·3 per 100 000 population (280·3-381·2) in men and 318·9 per 100 000 population (271·1-369·4) in women, and was similar among SDI quintiles. Global age-standardised mortality rates of idiopathic epilepsy were 1·74 per 100 000 population (1·64-1·87; 1·40 per 100 000 population [1·23-1·54] for women and 2·09 per 100 000 population [1·96-2·25] for men). Age-standardised DALYs were 182·6 per 100 000 population (149·0-223·5; 163·6 per 100 000 population [130·6-204·3] for women and 201·2 per 100 000 population [166·9-241·4] for men). The higher DALY rates in men were due to higher YLL rates compared with women. Between 1990 and 2016, there was a non-significant 6·0% (-4·0 to 16·7) change in the age-standardised prevalence of idiopathic epilepsy, but a significant decrease in age-standardised mortality rates (24·5% [10·8 to 31·8]) and age-standardised DALY rates (19·4% [9·0 to 27·6]). A third of the difference in age-standardised DALY rates between low and high SDI quintile countries was due to the greater severity of epilepsy in low-income settings, and two-thirds were due to a higher YLL rate in low SDI countries. INTERPRETATION: Despite the decrease in the disease burden from 1990 to 2016, epilepsy is still an important cause of disability and mortality. Standardised collection of data on epilepsy in population representative surveys will strengthen the estimates, particularly in countries for which we currently have no or sparse data and if additional data is collected on severity, causes, and treatment. Sizeable gains in reducing the burden of epilepsy might be expected from improved access to existing treatments in low-income countries and from the development of new effective drugs worldwide. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019. PMID: 30773428. doi:10.1016/S1474-4422(18)30454-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。